Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Onconova The Form 4 October 01, 20	-										
FORM	Л					OMB APPROVAL					
	UNITED	STATES		RITIES A shington			GE COMMISSION	OMB Number:	3235-		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Statement of Changes in Benefi Statement of Changes in Benefi Securities Filed pursuant to Section 16(a) of the Securit Section 17(a) of the Public Utility Holding Com 30(h) of the Investment Compan							Estimated average burden hours per response es Exchange Act of 1934, pany Act of 1935 or Section				
(Print or Type Res	ponses)										
1. Name and Address of Reporting Person <u>*</u> BANSAL AJAY			2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ONTX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O ONCONO THERAPEUT PHEASANT I	OVA TICS, INC., 37	Middle) 5		of Earliest T Day/Year) 2015	ransaction		Director X Officer (give below) Chief				
NEWTOWN,	(Street) PA 18940			endment, Da onth/Day/Yea	-	ıl	6. Individual or Jo Applicable Line) _X_ Form filed by 0 Form filed by N Person		erson		
(City)	(State)	(Zip)	Tah	ole I - Non-I	Derivative	Securiti	es Acquired, Disposed o	f. or Beneficia	llv Owned	1	
- · ·	Transaction Date Ionth/Day/Year)	2A. Deem Execution any (Month/D	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of 6 Securities F Beneficially (Owned (7. Nature Indirect	of Il ip	
Reminder: Report	on a separate line	e for each cl	lass of sec	urities benet	ficially ow	ned direc	tly or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

	1. Title of Derivative2.3. Transaction Date (Month/Day/Year)Security (Instr. 3)Or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
	Stock Option (right to purchase)	\$ 1.48	09/25/2015		А	32,500	<u>(1)</u>	09/25/2025	Common Stock	32,500	
Reporting Owners											
Reporting Owner Name / Address					Relationships						
				Director	10% Owner	Officer		Other			
BANSAL AJAY C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940			Chief Financial Officer								
	Signat	ures									
	/s/ Aiay B	ansal	10/01/2015								

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

/s/ Ajay Bansal 10/01/2015

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest over four years in 48 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.